Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Share-based Compensation (2016 - 2025)

Seres Therapeutics (MCRB) has disclosed Share-based Compensation for 11 consecutive years, with $3.2 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation fell 15.03% to $3.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $10.8 million through Dec 2025, down 48.31% year-over-year, with the annual reading at $10.8 million for FY2025, 48.31% down from the prior year.
  • Share-based Compensation hit $3.2 million in Q4 2025 for Seres Therapeutics, up from $2.5 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $13.5 million in Q2 2023 to a low of $2.3 million in Q2 2025.
  • Historically, Share-based Compensation has averaged $5.6 million across 5 years, with a median of $5.4 million in 2024.
  • Biggest five-year swings in Share-based Compensation: soared 165.31% in 2021 and later crashed 58.98% in 2024.
  • Year by year, Share-based Compensation stood at $5.7 million in 2021, then rose by 28.5% to $7.3 million in 2022, then tumbled by 30.24% to $5.1 million in 2023, then dropped by 25.97% to $3.8 million in 2024, then fell by 15.03% to $3.2 million in 2025.
  • Business Quant data shows Share-based Compensation for MCRB at $3.2 million in Q4 2025, $2.5 million in Q3 2025, and $2.3 million in Q2 2025.